A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email

We probably should start to use the term “Somatostatin Receptor PET” (SSTR PET) a bit more.  We got used to using the term Ga68 PET but since then we have an approved copper version known as 64Cu Dotatate (commercial brand name in US DETECTNET™).  Now we have another in the clinical trial pipeline and will add others as they come onto my radar.

Ga68 Dotatate/TOC/NOC – click here
Cu64 Dotatate (DetectNET) – click here

A Diagnostic Imaging Study of 64Cu-SARTATE™ Using Positron Emission Tomography (PET) on Patients With Known or Suspected NETs

Reference: NCT04438304

Trial status: Recruiting

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) NETs as a potential new way to help diagnose this type of cancer.

63 patient multicentre study run in Australia.

Clinical sites:

  • Royal North Shore Hospital
  • Peter MacCallum Cancer Centre
  • Royal Adelaide Hospital

How does it compare to Ga68 Dotatate?

Site: Peter MacCallum Cancer Centre,
Principal Investigator: Prof Rod Hicks

In comparison to 68Ga-DOTATATE scans, 64Cu-SARTATETM imaging in participants with NETs was equivalent at 1 hour, and superior at 4 hours, allowing detection of additional tumours at later time points.

Read more about SARTATE here.

Theranostics.  High late-retention in tumour and clearance from the liver suggests suitability for diagnostic studies as well as for prospective dosimetry for 67Cu-SARTATE PRRT (as at Apr 2021, being trialled with Neuroblastoma)

If you can see it, you can detect it.  Read more about Neuroendocrine Neoplasms imaging. 

Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document.  Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 

 
 

Thanks for reading.

Ronny

I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters –  Click Here 

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my Podcast Interview (click and press play)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

wego-blog-2018-winner

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email

I love comments - feel free!

%d bloggers like this: